fluorapacin

Fluorapacin is a novel fluorinated derivative of paclitaxel, belonging to the taxane class of antineoplastic agents. Developed by ACEA Biosciences, it is designed to enhance the therapeutic profile and potentially overcome resistance mechanisms associated with traditional taxanes. The drug functions as a microtubule stabilizer by binding to the beta-subunit of tubulin, which inhibits the disassembly of microtubules. This stabilization disrupts normal mitotic spindle dynamics, leading to cell cycle arrest at the G2/M phase and ultimately triggering apoptosis in rapidly dividing cancer cells. Fluorapacin has been evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, with a particular focus on patients with Stage IV lung cancer, to determine its safety, tolerability, and maximum tolerated dose.

Other names

FLP Injectionfluorinated paclitaxel